Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: Hypertension. 2012 Oct 8;60(5):1316–1323. doi: 10.1161/HYPERTENSIONAHA.112.199547

Figure 3. Effects of mitoTEMPO on MAP and heart rate.

Figure 3

A, ICV mitoTEMPO significantly attenuated MAP in Ang II-induced hypertension in a dose dependent manner (100 and 170ng/kg/min). B, Neither does of SC mitoTEMPO did not attenuate MAP. C, Heart rate did not show differences between mitoTEMPO treatment groups but Ang II infusion group. Bar graph is mean±SEM. *P<0.05, **P<0.01 vs control. N=7–8